Table 1.

Effect of calcium channel inhibitors on oocyte parthenogenetic activation

Inhibitor	Concentration	No. oocytes	Repeats	PA	PN	2-Cell
Ctrl		240	5	98.33 ± 1.24%	93.25 ± 5.32%	82.90 ± 7.53%
Tha	0.5 μM	240	5	84.2 ± 5.72%	65.7 ± 9.56%*	67.6 ± 7.59%
	1 μM	240	5	66.2 ± 9.24%	42.1 ± 8.56%*	26.1 ± 12.45%*
	10 μM	240	5	0	X	X
NS-8593	0.1 μM	240	5	83.3 ± 6.28%	75.2 ± 9.57%	86.7 ± 7.50%
	1 μM	240	5	37.5 ± 12.53%*	52.9 ± 7.84%*	57.7 ± 11.56%*
	5 μM	240	5	0	X	X
Mib	0.5 μM	240	5	77.3 ± 5.74%	55.6 ± 10.60%	67.5 ± 8.82%
	5 μM	240	5	36.7 ± 5.68%*	42.5 ± 5.93%*	66.4 ± 10.34%
	10 μM	240	5	3.6 ± 2.40%*	0	X
GSK-7975	10 μM	240	5	95.4 ± 3.21%	84.5 ± 6.34%	82.7 ± 7.26%
	100 μM	240	5	83.8 ± 5.21%	82.6 ± 5.83%	58.4 ± 11.57%
	1 mM	240	5	63.5 ± 7.95%*	0	X

Note:Tha indicates SERCAs inhibitor Thapsigargin. NS-8593 is a TRPM7 specific inhibitor. Mib indicates T-type Ca²⁺ channels inhibitor Mibefradil. GSK-7975A is an Orai1 specific inhibitor. PA indicates survival embryos of all activated oocytes after activation. PN indicates pronuclear embryos from surviving oocytes. 2-Cell indicates cleaved embryos in pronuclear fertilized eggs. “X” indicates none available data. The significance of differences between Inhibitors and Ctrl group were analyzed by the Chi-square test and p < 0.05 (*) was considered statistically significant